Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Income from Continuing Operations (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Income from Continuing Operations data on record, last reported at 364892000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 87.63% year-over-year to 364892000.0; the TTM value through Dec 2025 reached 1131301000.0, down 88.55%, while the annual FY2025 figure was 1131301000.0, 88.55% down from the prior year.
  • Income from Continuing Operations reached 364892000.0 in Q4 2025 per RVMD's latest filing, down from 305206000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 37176000.0 in Q1 2021 and bottomed at 364892000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 130233600.0, with a median of 103366000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: dropped 8.07% in 2022, then plummeted 185.15% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 52676000.0 in 2021, then dropped by 8.07% to 56927000.0 in 2022, then plummeted by 185.15% to 162329000.0 in 2023, then dropped by 19.8% to 194472000.0 in 2024, then plummeted by 87.63% to 364892000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 364892000.0 in Q4 2025, 305206000.0 in Q3 2025, and 247787000.0 in Q2 2025.